We can’t show the full text here under this license. Use the link below to read it at the source.
Dual and Triple Incretin-Based Co-agonists: Novel Therapeutics for Obesity and Diabetes
New Drugs Combining Two or Three Incretin Hormones to Treat Obesity and Diabetes
AI simplified
Abstract
The discovery of long-acting receptor agonists could significantly impact the treatment of obesity and diabetes.
- Multi-incretin hormone receptor agonists show promise in improving treatment efficacy for metabolic diseases.
- Current clinical trials are evaluating multiagonists that may rival the effectiveness of bariatric surgery.
- Success in both preclinical models and clinical trials indicates a potential for these agents in patient care.
- Further research is needed to clarify the mechanisms by which these therapies affect body weight.
- Understanding gut-brain communication may help develop strategies for sustainable weight loss without side effects.
AI simplified
Key numbers
22.5%
Average Weight Reduction with Tirzepatide
Achieved after 72 weeks of treatment in clinical trials.
−2.5%
Weight Reduction with GLP-1/GIP Dual Agonist
Observed after 12 weeks in a human study.